What Our Analysts Know About Rhythm Pharmaceuticals

By Chris Stiles • Thursday, December 11 15:23 • Permanent Link

Rhythm Pharmaceuticals logged a 14.0% change during today's afternoon session, and is now trading at a price of $119.47 per share. The S&P 500 index moved 0.0%. RYTM's trading volume is 2,671,757 compared to the stock's average volume of 655,950.

Anyone interested in buying RYTM should be aware of the facts below:

Rhythm Pharmaceuticals has moved 88.2% over the last year, and the S&P 500 logged a change of 13.8%
Based on its trailing earnings per share of -3.1, Rhythm Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -38.5 while the S&P 500 average is None
RYTM has a forward P/E ratio of -49.9 based on its forward 12 month price to earnings (EPS) of $-2.4 per share
Its Price to Book (P/B) ratio is 53.53 compared to its sector average of None
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
Based in Boston, the company has 283 full time employees and a market cap of $7.97 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.